Important Information for Maravai Lifesciences Holdings, Inc. (MRVI) Investors: Rosen Law Firm Reminds of Class Action Lawsuit Deadline
New York, NY – March 25, 2025
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Maravai Lifesciences Holdings, Inc. (MRVI) securities between August 7, 2024 and February 24, 2025, both dates inclusive (the “Class Period”), of the upcoming May 5, 2025 lead plaintiff deadline. If you purchased Maravai securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
What Happened to Maravai Lifesciences Holdings, Inc.?
According to the lawsuit, the defendants, including certain Maravai executives and directors, made false and/or misleading statements and/or failed to disclose that:
- Maravai’s financial statements for the periods ending December 31, 2023 and 2022 contained material misstatements and/or omissions;
- Maravai’s revenues and earnings were not growing as represented;
- Maravai’s research and development efforts were not progressing as planned;
- Maravai’s financial condition was weaker than reported;
- Maravai was experiencing significant competition in the market.
As a result of these allegations, Maravai’s stock price has suffered significant declines, causing harm to investors.
What Does This Mean for MRVI Investors?
If you purchased Maravai securities during the Class Period and suffered losses, you may be entitled to compensation. The lead plaintiff deadline for this class action lawsuit is May 5, 2025. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2025. To be a lead plaintiff, you must meet certain legal requirements.
If you wish to join the class action lawsuit, you do not need to act at this time. You may retain counsel of your choice. You will be represented in this lawsuit by Rosen Law Firm, P.A., which has significant experience in securities class action litigation.
What Does This Mean for the World?
The Maravai class action lawsuit is an important reminder for investors to carefully evaluate the information provided by companies and their executives before making investment decisions. Misrepresentations and omissions can lead to significant financial losses for investors. It also highlights the importance of having a robust regulatory framework in place to protect investors and ensure transparency in financial reporting.
Conclusion
If you purchased Maravai Lifesciences Holdings, Inc. securities between August 7, 2024 and February 24, 2025, and suffered losses as a result, you may be entitled to compensation. The lead plaintiff deadline for this class action lawsuit is May 5, 2025. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2025. For more information, contact Rosen Law Firm at (866) 767-3653 or [email protected] The lawsuit seeks to recover damages for Maravai investors.
This is not a solicitation or an offer to buy securities, and it is not a class action lawsuit. The lawsuit is only intended to provide investors with information about their rights and options.
If you have any questions, please contact us.
